303 related articles for article (PubMed ID: 15980336)
21. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Pérez-Victoria FJ; Sánchez-Cañete MP; Seifert K; Croft SL; Sundar S; Castanys S; Gamarro F
Drug Resist Updat; 2006; 9(1-2):26-39. PubMed ID: 16814199
[TBL] [Abstract][Full Text] [Related]
23. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
26. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
27. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Kothari H; Kumar P; Sundar S; Singh N
Parasitol Int; 2007 Mar; 56(1):77-80. PubMed ID: 17169604
[TBL] [Abstract][Full Text] [Related]
28. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
29. Hexadecylphosphocholine interaction with lipid monolayers.
Rakotomanga M; Loiseau PM; Saint-Pierre-Chazalet M
Biochim Biophys Acta; 2004 Mar; 1661(2):212-8. PubMed ID: 15003884
[TBL] [Abstract][Full Text] [Related]
30. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Imbert L; Ramos RG; Libong D; Abreu S; Loiseau PM; Chaminade P
Anal Bioanal Chem; 2012 Jan; 402(3):1169-82. PubMed ID: 22065347
[TBL] [Abstract][Full Text] [Related]
31. Leishmania resistance to miltefosine associated with genetic marker.
Cojean S; Houzé S; Haouchine D; Huteau F; Lariven S; Hubert V; Michard F; Bories C; Pratlong F; Le Bras J; Loiseau PM; Matheron S
Emerg Infect Dis; 2012 Apr; 18(4):704-6. PubMed ID: 22469394
[No Abstract] [Full Text] [Related]
32. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
33. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Das M; Saha G; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
[TBL] [Abstract][Full Text] [Related]
34. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
35. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
Singh N; Dube A
Am J Trop Med Hyg; 2004 Oct; 71(4):400-2. PubMed ID: 15516633
[TBL] [Abstract][Full Text] [Related]
36. Studies on stibanate resistant Leishmania donovani isolates of Indian origin.
Pal S; Mandal A; Duttagupta S
Indian J Exp Biol; 2001 Mar; 39(3):249-54. PubMed ID: 11495284
[TBL] [Abstract][Full Text] [Related]
37. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca
Pinto-Martinez AK; Rodriguez-Durán J; Serrano-Martin X; Hernandez-Rodriguez V; Benaim G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061745
[No Abstract] [Full Text] [Related]
39. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Papagiannaros A; Bories C; Demetzos C; Loiseau PM
Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
[TBL] [Abstract][Full Text] [Related]
40. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
